One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
enVVeno Medical Corporation
NVNO · NCM · Healthcare · Medical Devices
Current price
$6.52
52-week range
$6.26 - $24.36
Market cap
$4.53M
Balance sheet
Healthy
-30.20x Concerning
Net cash $18.06M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -67.1% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 8.1% (peer median: 16.3%).
What this company does
enVVeno Medical Corporation
enVVeno Medical Corporation makes medical devices to treat vein problems, with their main product being a surgical valve replacement called VenoValve, and they are also developing a less invasive valve system. The company's income primarily comes from selling these specialized medical devices, and this matters because it shows how they plan to make money from their innovative treatments for vein conditions.
How the company got here
enVVeno Medical Corporation, originally founded as Hancock Jaffe Laboratories, Inc. in 1999, has evolved significantly in its mission to address venous diseases. The company officially changed its name to enVVeno Medical Corporation in October 2021, signaling a renewed focus on its innovative medical device solutions. This rebranding marked a strategic shift, particularly after facing regulatory hurdles with its initial product. The company's journey has been characterized by a persistent effort to develop advanced treatments for a condition with limited effective options, navigating the complex landscape of medical device development and regulatory approval. Its history is rooted in the pursuit of improving patient care through bioprosthetic tissue-based technologies.
What it actually does
enVVeno Medical Corporation develops and aims to commercialize medical devices designed to treat venous diseases, particularly chronic venous insufficiency. These conditions occur when the valves in the leg veins become damaged, leading to blood pooling and discomfort. The company's core focus is on creating replacement venous valves that restore proper blood flow from the legs back to the heart. Their goal is to significantly improve the quality of life for patients suffering from debilitating venous conditions, offering solutions where few effective treatments currently exist. The company's work is centered on improving the standard of care in the United States for these challenging medical issues.
enVVe System
The enVVe System represents enVVeno Medical's primary focus and future strategy. It is a first-in-class, non-surgical replacement venous valve delivered through a minimally invasive procedure using a catheter. This approach aims to restore one-way blood flow in the deep veins of the leg, addressing the root cause of severe deep venous insufficiency (DVI). Unlike traditional open surgery, the enVVe system is designed to avoid general anesthesia and overnight hospital stays, making it a less burdensome option for patients. The company is actively advancing the enVVe system through clinical trials, including the TAVVE pivotal study, which has received FDA Investigational Device Exemption (IDE) approval. This segment is considered the company's main growth driver and its primary bet for future success in the multi-billion-dollar venous disease market.
VenoValve
The VenoValve was enVVeno Medical's initial lead product, designed as a surgical replacement venous valve for treating severe chronic venous insufficiency (CVI). This device was intended for implantation via an open surgical procedure. However, the company received a 'not approvable' letter from the U.S. Food and Drug Administration (FDA) for its Premarket Approval (PMA) application for the VenoValve. This regulatory setback indicated that the FDA could not approve the application in its current form, citing concerns about the benefit-risk profile and safety issues related to the surgical procedure. While the company has explored options for the VenoValve, including an appeal, its strategic focus has largely shifted to the less invasive enVVe system.
What management is betting on now
Management at enVVeno Medical is heavily focused on the development and advancement of the enVVe System, a non-surgical, transcatheter-based replacement venous valve. This strategic pivot follows the FDA's decision regarding the VenoValve, with the company accelerating its efforts on the less invasive enVVe approach. Key priorities include successfully executing the TAVVE pivotal study, which is designed to evaluate the enVVe system's safety and efficacy. Management is also focused on building clinical evidence and securing reimbursement pathways to support future commercialization. The company believes the enVVe system has the potential to transform the treatment paradigm for deep chronic venous insufficiency and capture a significant share of a large, underserved market.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q4
$-5.11M
FY2025 Q2
$-3.72M
FY2025 Q3
$-4.39M
FY2025 Q4
$-3.44M
Revenue
—
Net income
$-4.37M
Diluted EPS
-6.29
Operating cash flow
$-3.18M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.60M
Diluted EPS
-5.37
Operating cash flow
$-3.55M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.85M
Diluted EPS
-5.89
Operating cash flow
$-3.24M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.74M
Diluted EPS
-32.28
Operating cash flow
$-3.44M
Free cash flow
$-3.44M
Fetching…
Sources
Revenue
—
Net income
$-4.54M
Diluted EPS
-0.23
Operating cash flow
$-4.39M
Free cash flow
$-4.39M
Fetching…
Sources
Revenue
—
Net income
$-6.69M
Diluted EPS
-0.33
Operating cash flow
$-3.71M
Free cash flow
$-3.72M
Fetching…
Sources
Revenue
—
Net income
$-4.50M
Diluted EPS
-0.22
Operating cash flow
$-4.02M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-6.23M
Diluted EPS
-0.30
Operating cash flow
$-5.11M
Free cash flow
$-5.11M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $6.52
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $18.1M - more cash than debt. Interest coverage -30.2x.
Net debt
$-18.06M
Interest coverage
-30.20x
enVVeno Medical Corporation's profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 5 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
NVNO
BASELINE
enVVeno Medical Corporation
Total debt $408.00K Interest coverage -30.20x This is the baseline the peer rows are being compared against.
Total debt $90.00K Interest coverage -407.95x Neither company has much profit cushion over interest right now.
Total debt $29.43M Interest coverage -5.45x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -9.76x Neither company has much profit cushion over interest right now.
Total debt $1.79M Interest coverage -1,146.57x Neither company has much profit cushion over interest right now.
Total debt $11.41M Interest coverage -8.53x Neither company has much profit cushion over interest right now.
What you should know
The case for and against NVNO
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -67.1% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 8.1% (peer median: 16.3%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.05x
P/B
0.27x
P/S
—
EV/EBITDA
0.81x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-67.1%
ROA
-40.4%
Health
Liquidity and balance-sheet strength
Debt / equity
0.02x
Current ratio
7.35x
Quick ratio
7.13x
Total debt
$408.00K
Total cash
$18.47M
Growth
How the business has been compounding
Revenue TTM
$31.24K
Revenue 5Y CAGR
-59.1%
EPS TTM
-23.27
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-13.41M
Free CF TTM
$-15.57M
FCF margin
-49,844.8%
Dividend
Shareholder payout
Yield
0.0%
Payout ratio
—
Last ex-div date
—